Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Pfizer Inc. PFE and partner Arvinas Inc. ARVN shares rose Monday after the companies secured a key regulatory win, with the U ...
Pfizer Inc. PFE on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab) ...
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on ...
(PFE) is running a Phase 2 trial of ritlecitinib in adults with moderate to severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps. The study, officially titled “A Phase 2, ...
The decisions by Pfizer and Merck to share their COVID-19 drug patents stands in stark contrast to the refusal of Pfizer and other vaccine-makers to release their vaccine recipes ...
Pfizer said its blood-cancer treatment met the main goal of an ongoing late-stage study, significantly extending the time patients lived without their disease worsening compared with a standard drug ...
(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...
Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic ...
Just The News on MSN
Pfizer's COVID antiviral, bankrolled by Biden administration, doesn't help high-risk adults: study
New England Journal of Medicine lets Anthony Fauci and his onetime deputy play down results in editorial alongside study from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results